Home / Carboplatin / United States
US ATC L01XA02 · updated 2 Nov 2026
Carboplatin shortage in United States
Is there a Carboplatin shortage in United States?
Yes. As of 2 Nov 2026, 35 Carboplatin products are reported short in United States, the first since 28 Apr 2023. No return date has been given. Main reason: not stated.
Also short in Canada, Germany, Italy, Spain, Belgium, Switzerland, Czechia, Sweden, Japan. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) limited | Teva Pharmaceuticals USA, Inc. | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) | Teva Pharmaceuticals USA, Inc. | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) | Teva Pharmaceuticals USA, Inc. | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) limited | Teva Pharmaceuticals USA, Inc. | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) | Accord Healthcare Inc. | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) | Accord Healthcare Inc. | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) | Accord Healthcare Inc. | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) | Accord Healthcare Inc. | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) | Fresenius Kabi USA, LLC | 28 Apr 2023 | not given | Distribution or logistics Delay in shipping of the drug |
| US | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) limited | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 150 mg/15 mL (NDC 69339-365-15) | Teyro Labs | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | Gland Pharma Limited | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) limited | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | Eugia US LLC | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 450 mg/45 mL (NDC 69339-366-45) | Teyro Labs | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) limited | Gland Pharma Limited | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) limited | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 50 mg/5 mL (NDC 69339-364-05) | Teyro Labs | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) discontinuation | Gland Pharma Limited | 28 Apr 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) limited | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) | Hospira, Inc., a Pfizer Company | 28 Apr 2023 | not given | Other |
| US | Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | Eugia US LLC | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 600 mg/60 mL (NDC 69339-367-60) | Teyro Labs | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) limited | Gland Pharma Limited | 28 Apr 2023 | not given | Increased demand Demand increase for the drug |
| US | Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) | Avyxa Pharma, LLC | 28 Apr 2023 | not given | Not stated |
| US | Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) | Avyxa Pharma, LLC | 28 Apr 2023 | not given | Not stated |
| US | Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) discontinuation | Ingenus Pharmaceuticals LLC | 20 Feb 2026 | not given | Not stated |
| US | Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) discontinuation | Ingenus Pharmaceuticals LLC | 20 Feb 2026 | not given | Not stated |
| US | Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) discontinuation | Teyro Labs | 1 Jun 2026 | not given | Not stated |
| US | Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) discontinuation | Teyro Labs | 1 Jun 2026 | not given | Not stated |
| US | Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) discontinuation | Teyro Labs | 1 Jun 2026 | not given | Not stated |
| US | Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) discontinuation | Teyro Labs | 1 Jun 2026 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).